On the Prohibition of Conflicts of Interest in Pharmaceutical Regulation: Precautionary Limits and Permissive Challenges. a Commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin
Social Science & Medicine (1982) 2010 March; 70(5): 648-651
Showing items related by title, author, creator and subject.
Prohibiting or 'Managing' Conflict of Interest? A Review of Policies and Procedures in Three European Drug Regulation Agencies Lexchin, Joel; O'Donovan, Orla (2010-03)In light of debates about the relationship between interests and scientific expert judgments, and the potential for declarations of conflict of interest (COI) to minimize corporate bias, we reviewed the approach to COI in ...
Abraham, John (2009-12)Coinciding with sixty years of the U.K. National Health Service (NHS), this article reviews the neglected area of the governance of the pharmaceutical industry and the NHS. It traces the relationships between the pharmaceutical ...
Rochon, Paula A; Sekeres, Melanie; Hoey, John; Lexchin, Joel; Ferris, Lorraine E; Moher, David; Wu, Wei; Kalkar, Sunila R; Van Laethem, Marleen; Gruneir, Andrea; Gold, Jennifer; Maskalyk, James; Streiner, David L; Taback, Nathan; Chan, An-Wen (2011-01-12)Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce their objectivity. We obtained information from investigators about adherence to practices that minimize the introduction ...